Азитромицин в пульмонологической практике: 20 лет спустя

1. Rangel-Frausto M, Pittet D, Costigan M et al. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273: 117–23.
2. Klein J. Pediatr Infect. Dis J 1997; 16 (4): 427–34.
3. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической     практике. http://www.antibiotic.ru/books/macrolid/intro.shtml.
4. Ferech M, Coenen S, Malhotra-Kumar S et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58 (2): 401–7.
5. McCaig L, Besser R, Hughes J. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis 2003; 9 (4): 432–7.
6. Metz-Gercek S, Maieron A, Strau R et al. Ten years of antibiotic consumption in ambulatory care: Trends in prescribing practice and antibiotic resistance in Austria. BMC Infectious Diseases 2009. http://www.biomedcentral.com/1471–2334/9/61.
7. Williams J, Sefton A. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993; 31 (Suppl. C): 11–26.
8. Odenholt-Tornqvist I, Lowdin E, Cars O. Postantibiotic effects and postantibiotic sub-MIC effects of roxithromycin, clarithromycin, and azithromycin on respiratory tract pathogens. Antimicrob Agents Chemother 1995; 39: 221–6.
9. Ball P. Therapeutic considerations for the management of respiratory tract infections. The role of new macrolides and fluoroquinolones. Infect In Med 1991; 8 (Suppl. A): 7–17.
10. Peters D, Clissold S. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potencial. Drugs 1992; 44 (1): 117–64.
11. Козлов Р.С., Веселов А.В. Макролиды и кетолиды. В кн.: Внебольничные инфекции дыхательных путей: диагностика и лечение. М., 2008; с. 49–65.
12. Schito G, Debbia E, Marchese A. The evolving threat of antibiotic resistance in Europe: new data from the Alexander project. J Antimicrob Chemother 2000; 46 (1): 3–9.
13. Решедько Г.К., Козлов Р.С. Состояние резистентности к антиинфекционным химиопрепаратам в России. В кн.: Практическое руководство по антиинфекционной химиотерапии. Под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.И.Козлова. М., 2007; с. 32–47.
14. Dunn C, Barradell L. Azithromycin: a review of its pharmacologal properties and use as 3-day therapy in respiratory tract infections. Drugs 1996; 51: 483–505.
15. Bergan T. Pharmacokinetics of newer macrolides. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (eds.). New York, etc., 1995; 51–60.
16. Gialdroni Grassi G, Grassi C. Clinical application of macrolides and azalides in Legionella, Mycoplasma, and Chlamydia respiratory infections. In: New Macrolides, Azalides, and Streptogramins in Clinical Practice. Neu HC, Young LS, Zinner SH, Acar JF. (eds.). New York, etc., 1995; 147–54.
17. Wildfeurer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother 1996; 40: 75–9.
18. Хенд В.Л., Хенд Д.Л. Механизмы накопления и выброса азитромицина в полиморфонуклеарных лейкоцитах человека. Антибиот. и химиотер. 2002; 47 (7): 6–12.
19. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004; 125: 41–51.
20. Culic O, Erakovich V, Pamham M. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429: 209–29.
21. Treadway G, Pontani D. Paediatric savety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37 (suppl. C): 143–9.
22. Ioannidis J, Contopoulos-Ioannidis D, Chew P, Lau J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for upper respiratory tractinfections. J Antimicrob Chemoter 2001; 48: 677–89.
23. Zimmermann T, Riedel K, Laufen H et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin. In: The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, 1996: A82.
24. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63: 2169–84.
25. Guillemot D, Carbon C, Balkau B et al. Low dosage and long treatment duration of ?-lactam: risk factors for carrige of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365–70.
26. Amsden G, Nafziger A, Foulds G. Abstr. of The 4-th Intern. Conference on the macrolides, azalides, streptogramins & ketoldes, Barselona 1998; 109: abstr.12.05.
27. Шпынев К.В., Кречиков В.А. Современные подходы к диагностике стрептококкового фарингита. Клин. микроб. антимикроб. химиотер. 2007; 9 (1): 20–33.
28. Страчунский Л.С., Тарасов А.А., Крюков А.И. и др. Возбудители острого бактериального синусита. Результаты многоцентрового микробиологического исследования SSSR. Клин. микроб. антимикроб. химиотер. 2005; 7 (4): 337–49.
29. Sinus and Allergy Health Partner-ship. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surgery 2000; 123: 1–32.
30. Чучалин А.Г., Синопальников А.И., Страчунский Л.С. и др. Внебольничная пневмония у взрослых. Практические рекомендации по диагностике, лечению и профилактике. М.: OOO «Издательский дом «М-Вести», 2006.
31. Mandell L, Richard G et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. http://www.thoracic.org/sections/publications/statements/pages/mtpi/ idsaats-cap.html.
32. Синопальников А.И., Зайцев А.А. Клиническая эффективность и безопасность ступенчатой монотерапии азитромицином у пациентов с внебольничной пневмонией в условиях стационара. Фарматека. 2006; 16 (131): 66–72.
33. Гучев И.А., Клочков О.И. Антибиотикопрофилактика вспышек внебольничной пневмонии в гомогенной популяции. http://medi.ru/doc/1475157.htm.
34. Синопальников А.И., Козлов Р.С., Романовских А.Г., Рачина С.А. Инфекционное обострение ХОБЛ: практические рекомендации по диагностике, лечению и профилактике. Рос. мед. вести. 2006; 11 (1): 4–18.
35. Tsang K, Ho P, Chan K et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13: 361–5.
36. Saiman L, Marshall B, Mayer-Hamblett N et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749–53.
37. Чучалин А.Г., Черняев А.Л. Бронхиолиты. http://www.rmj.ru/articles_530.htm.
38. Kobayashi H, Shimada K, Nakata K et al. Study on azithromycin in treatment of diffuse panbronchiolitis. In: The 3rd International Conference on the Macrolides, Azalides and Streptogramins. Lisbon, 1996; abstr. 9.12.
39. Радионович А.М., Каширская Н.Ю., Капранов Н.И. Длительное применение макролидов при хронической синегнойной инфекции у больных муковисцидозом. http://www.consiliummedicum.com/media/pediatr/06_01/68.shtml.
40. Carr R, Nahata M. Azithromycin for improving pulmonary function in cystic fibrosis. Ann Pharmacother 2004; 38 (9): 1520–4.
41. Southern K, Barker P, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004; 2: CD002203.
42. Steinkamp G et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008; http://www.antibiotic.ru/index.php?article=1724.
43. McCormack et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007; 30: 487–95.
44. Hahn D. Chlamydia pneumoniae, asthma and CORD: what is the evidence? Ann Allergy Asthma Immunol 1999; 83: 271–88.
45. Allegra L, Blasi F, Centanni S et al. Acute exacerbations of asthma in adults: role of Chlamydia pneumoniae infection. Eur Respir J 1994; 7 (12): 2165–8.
46. Miyashita N, Kubota Y, Nakajima M et al. Chlamydia pneumoniae and exacerbations of asthma in adults. Ann Allergy Asthma Immunol 1998; 80 (5): 405–9.
47. Kraft M, Cassell G, Aerni M et al. Mycoplasma pneumoniae as a cofactor in the pathogenesis of chronic asthma. In: European Respiratory Society. Annual Congress. Berlin 1997; abstr. P0292.
48. Jenkins C, Blasi F, Allegra L et al. Chlamydia pneumoniae asthma roxithromycin multinational study (CARM); seroprevalence results. In: The 4th International Conference on the Macrolides, Azalides, Streptogramins & Ketolides. Barcelona, 1998; abstr. 4.22.
49. Белоцерковская Ю.Г, Казаков С.П., Синопальников А.И. Бронхиальная астма, ассоциированная с Chlamydia pneumoniaeинфекцией. Клин. микроб. антимикроб. химиотер. 2007; 9 (3): 233-43.